Literature DB >> 15643343

Airway wall remodelling: the influence of corticosteroids.

Chris Ward1, Haydn Walters.   

Abstract

PURPOSE OF THE REVIEW: We have attempted to bring together recent findings, mainly from airway endobronchial biopsies, on the structural changes that constitute 'remodelling' in airway disease, with a particular focus on asthma. We have tried to put this into the context of classic studies on the asthma pathological phenotype. Having described these basic changes, we have then given an update on recent studies investigating the effects of corticosteroid medication on the different manifestations of remodelled airways. RECENT
FINDINGS: The effects of corticosteroid on airway remodelling seem to vary a great deal; some aspects are steroid responsive while others are not, or less so. It is likely that different manifestations of remodelling require different doses and timescales for treatment to be effective.
SUMMARY: Further longitudinal interventional studies are required, with multiple airway sampling times, to fully elucidate the full potential for corticosteroids to benefit remodelling of the airways in chronic inflammatory diseases. There needs to be more attention to pathophysiological and clinical correlations in such studies. It is likely that even when used optimally corticosteroids will have limited efficacy overall in this aspect of asthma pathogenesis. The search is on for newer and better treatments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15643343     DOI: 10.1097/00130832-200502000-00009

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  14 in total

1.  The effect of inhaled budesonide and formoterol on bronchial remodeling and HRCT features in young asthmatics.

Authors:  Firuz Capraz; Erdogan Kunter; Hakan Cermik; Ahmet Ilvan; Suheyl Pocan
Journal:  Lung       Date:  2007-03-28       Impact factor: 2.584

Review 2.  Allergen-induced airway remodelling.

Authors:  C M Lloyd; D S Robinson
Journal:  Eur Respir J       Date:  2007-05       Impact factor: 16.671

3.  CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling.

Authors:  Jennifer Kearley; Douglas S Robinson; Clare M Lloyd
Journal:  J Allergy Clin Immunol       Date:  2008-07-30       Impact factor: 10.793

4.  The Difficult-to-Control Asthmatic: A Systematic Approach.

Authors:  Annie V Le; Ronald A Simon
Journal:  Allergy Asthma Clin Immunol       Date:  2006-09-15       Impact factor: 3.406

5.  Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.

Authors:  Lena Uller; Jesper Mosolff Mathiesen; Lisa Alenmyr; Magnus Korsgren; Trond Ulven; Thomas Högberg; Gunnar Andersson; Carl G A Persson; Evi Kostenis
Journal:  Respir Res       Date:  2007-02-28

Review 6.  Chronic inflammation and asthma.

Authors:  Jenna R Murdoch; Clare M Lloyd
Journal:  Mutat Res       Date:  2009-09-19       Impact factor: 2.433

7.  Inhibition of Angiogenic Factor Productions by Quercetin In Vitro and In Vivo.

Authors:  Takayuki Okumo; Atsuko Furuta; Tarou Kimura; Kanako Yusa; Kazuhito Asano; Masataka Sunagawa
Journal:  Medicines (Basel)       Date:  2021-05-12

8.  Inhibition of angiogenic factor production from murine mast cells by an antiallergic agent (epinastine hydrochloride) in vitro.

Authors:  K Asano; A Furuta; K Kanai; S Sakaue; H Suzaki; T Hisamitsu
Journal:  Mediators Inflamm       Date:  2008       Impact factor: 4.711

9.  In vitro effects of budesonide on eosinophil-basophil lineage commitment.

Authors:  Michael M Cyr; Adrian J Baatjes; Sandra C Dorman; Lynn Crawford; Roma Sehmi; Ronan Foley; Rafeul Alam; Paul O' Byrne; Judah A Denburg
Journal:  Open Respir Med J       Date:  2008-06-13

10.  Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease.

Authors:  Jane Elizabeth Ward; Xiahui Tan
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.